Henri Lichenstein, Ph. D.

Henri Lichenstein, Ph.D.

Henri Lichenstein is the President and CEO of LAM Therapeutics. Dr. Lichenstein has over 30 years of drug development experience at Amgen, CuraGen Corporation, Topotarget, and BioPontis Alliance, and has led numerous successful drug development efforts resulting in the advancement of therapeutics from discovery into clinical development. At Topotarget and CuraGen Corporation, Dr. Lichenstein led the global pre- and clinical development of the histone deacetylase inhibitor, belinostat, in over 20 oncology clinical trials, including a registration study in peripheral T-cell lymphoma that led to drug approval by the FDA. Dr. Lichenstein also has significant business development and transaction experience, having closed deals (both in- and out-licensing) and financing worth in excess of $1B. Dr. Lichenstein earned his Ph.D. in Biochemistry and Molecular Biology from the University of California, Santa Barbara and is co-author and inventor on over 50 publications and 60 patents, respectively.

Tian Xu, Ph. D.

Tian Xu, Ph.D.

Tian Xu serves on LAM Therapeutics Scientific Advisory Board. Dr. Xu is Professor and Vice Chair of Genetics at Yale University School of Medicine and a Howard Hughes Medical Institute Investigator. He also serves as Director of the Institute of Developmental Biology and Molecular Medicine at Fudan University in Shanghai. He was President of the Chinese Biological Investigators Society and Chair of the Scientific Advisory Board for the Rothberg Institute for Childhood Diseases. The major thrust of Xu’s research effort lies in developing and utilizing novel genetic approaches to understand Development and Disease. The systematic functional genetics methods that he developed for Drosophila, mice and human cells have been used by the research community throughout the world. He is also the pioneer and leader for Growth and Size Control and identified the major pathways including TSC/Tor, that regulate growth in development and tumorigenesis. His recent work showing oncogenic cooperation for mutations in different neighboring cells brought new concept and the examination of tumor genetic heterogeneity for cancer biology and therapy.

Peter Young

Peter Young, Ph.D.

Peter Young is the Head of Research and Translational Sciences at LAM Therapeutics. Dr. Young has over 25 years of experience in target identification, validation, drug discovery and development while holding various executive and management positions at SmithKline Beecham, DuPont Pharmaceuticals, SUGEN, Celera, Genelabs, Affymax and Resverlogix. He has worked in multiple therapeutic areas such as oncology, autoimmune/inflammation, hematology, metabolic and anti-viral disease and has contributed to the discovery and/or development of Promacta® for Idiopathic Thrombocytopenia Purpura, Imbruvica® for hematological cancer, Nucala® for severe eosinophilic asthma and several products in early clinical development, including apabetalone for atherosclerosis, abexinostat for lymphoma and a cathepsin S inhibitor for psoriasis. As VP Research at Affymax, Peter supported the CMC, translational, non-clinical safety and immunogenicity aspects of the development of Omontys®, a once a month pegylated peptidic erythropoietic agent, for the treatment of anemia. Peter is co-author on over 120 papers and co-inventor on 34 issued patents.

Robert Spiegel, M.D. FACP

Robert Spiegel, M.D. FACP

Robert Spiegel joined the LAM Therapeutics Scientific Advisory Board in April, 2013. Dr. Spiegel is the founder of Spiegel Consulting LLC, an independent advisory firm to pharmaceutical and biotechnology companies, and serves as a Senior Advisor to Warburg Pincus and BioPontis Alliance. He retired in 2009 as Chief Medical Officer at Schering-Plough. With 25+ years experience in the pharmaceutical industry, he played a significant role in the development of novel biologics and drugs as Senior VP of Worldwide Clinical Research. Prior to joining Schering-Plough, Dr. Spiegel was an Assistant Professor, Department of Medicine, NYU Medical Center. Dr. Spiegel obtained his M.D. from the University of Pennsylvania and a B.A., cum laude, from Yale University. He received his training in Medical Oncology as a Research Associate at the National Cancer Institute, NIH. He currently serves on the Boards of numerous biotechnology companies and nonprofits and is an Assistant Professor of Medicine at Cornell Weill Medical College and Associate Fellow in the University of Pennsylvania Center for Bioethics.

Brendan D. Manning, Ph.D.

Brendan Manning, Ph.D.

Brendan Manning joined the LAM Therapeutics Scientific Advisory Board in May, 2013. Dr. Manning is a Professor in the Department of Genetics and Complex Diseases at the Harvard School of Public Health (HSPH). His doctoral training was in the laboratory of Michael Snyder at Yale University, where he worked basic mechanisms of cell division. Following receipt of his Ph.D. in 2000, Dr. Manning joined the laboratory of Lewis Cantley at Harvard Medical School for his postdoctoral research. During this time, he identified the tuberous sclerosis complex (TSC) tumor suppressor as the molecular connection between the PI3K and mTOR pathways, thereby linking a signaling pathway activated in the majority of human cancers to a nutrient-sensing pathway that controls cell growth and metabolism. In 2004, Dr. Manning joined the faculty of the then newly established Department of Genetics and Complex Diseases at HSPH to continue research at the interface of cancer and metabolism. He serves on multiple editorial boards, the Scientific Advisory Board of the LAM Foundation, and the Science and Medical Committee of the Tuberous Sclerosis Alliance.

Lawrence Melvin, Ph.D.

Larry Melvin joined the LAM Therapeutics Scientific Advisory Board in November, 2013. Dr. Melvin has over 30 years of experience in drug discovery and development with Pfizer, Amgen, Myogen and Gilead. Dr. Melvin has a broad background in medicinal chemistry including the areas of inflammation, respiratory, cardiovascular, central nervous system and antibacterial. He has initiated and led successful drug discovery programs yielding compounds for clinical study and participated in successful development programs such as Letairis™ for pulmonary arterial hypertension. Dr. Melvin earned his Ph.D. in synthetic organic chemistry from the University of Wisconsin and completed postdoctoral studies in organic synthesis at Harvard University. He is co-author or inventor on over 60 publications and over 60 issued US patents.

Joel Bader

Joel S. Bader, Ph.D.

Joel Bader joined the LAM Therapeutics Scientific Advisory Board in December, 2014. Dr. Bader is an Associate Professor in the Department of Biomedical Engineering, Johns Hopkins University, and is Interim Director of the High-Throughput Biology Center at the Johns Hopkins School of Medicine. He is a member of the Institute of Computational Medicine and the Institute of Genetic Medicine, and he holds a secondary appointment in the Department of Computer Science at Johns Hopkins. Prior to joining Johns Hopkins in 2003, Dr. Bader was Director of Bioinformatics at CuraGen Corporation, where he co-invented the 454 Genome Sequencer with LAM founder Dr. Jonathan Rothberg and helped lead the generation of proteome-scale protein-protein interaction maps for yeast, fruit fly, and human. Dr. Bader’s research at Johns Hopkins focuses on systems biology, synthetic biology, and human disease genetics. Dr. Bader is co-founder of Neochromosome, Inc., a synthetic biology company. He received his Ph.D. in 1992 from U.C. Berkeley, where he was an NSF Predoctoral Fellow, and received an NSF CAREER Award while at Johns Hopkins.

Joel Dudley

Joel Dudley, Ph.D.

Joel Dudley joined the LAM Therapeutics Scientific Advisory Board in December, 2014. Dr. Dudley is Assistant Professor of Genetics and Genomic Sciences and Director of Biomedical Informatics at the Icahn School of Medicine at Mount Sinai in New York City. Dr. Dudley obtained his PhD in Biomedical Informatics from Stanford University School of Medicine, where he developed research in the areas of genomic medicine and translational bioinformatics. Prior to Mount Sinai, he held positions as Co-founder and Director of Informatics at NuMedii, Inc. and Consulting Professor of Systems Medicine in the Department of Pediatrics at Stanford University. His current research is focused towards solving key challenges in precision medicine through the development and application of translational and biomedical informatics methodologies. His lab publishes in the areas of bioinformatics, genomic medicine, personal genomics, as well as drug and biomarker discovery. His previous work with co-authors describing a novel systems based approach for computational drug repositioning was featured in the print edition of the Wall Street Journal, and earned designation as the NHGRI Director’s Genome Advance of the Month. Dr. Dudley is co-author of the book Exploring Personal Genomics from Oxford University Press, and he was recently named by Fast Company magazine as one of the 100 Most Creative People in Business (2014).

Paul Beckett, Ph.D.

Paul Beckett, Ph.D.

Paul Beckett joined LAM Therapeutics as Senior Director, Drug Discovery in August, 2013. He is an internationally experienced medicinal chemist and drug discovery leader with a background in emerging biotech/pharmaceutical companies. He played a prominent role in the establishment of British Biotech Pharmaceuticals, the UK’s first publicly traded biotech company, where he contributed extensively to the discovery of the matrix metalloproteinase inhibitor BB-2516 (Marimastat, reached Phase III clinical trials in cancer) and the antibacterial agent BB-83698 (first-in-class to enter human clinical trials). As Director of Chemistry at Cara Therapeutics, he built the medicinal chemistry department from inception and initiated the discovery of a novel series of orally bioavailable, peripherally restricted, cannabinoid receptor agonists for the treatment of pain, as well as overseeing several other early stage projects. Most recently with the Institutes for Pharmaceutical Discovery, Paul was involved in multiple successful projects including the discovery of a novel series of arginase inhibitors with broad therapeutic potential. He is named as inventor on over 40 issued US patents and is an author on 35 scientific publications.